Compare
Penumbra Inc vs Haemonetics Corp vs Integra Lifesciences Holdings Corp vs Tandem Diabetes Care Inc
| Latest fiscal year | Penumbra Inc PEN | Haemonetics Corp HAE | Integra Lifesciences Holdings Corp IART | Tandem Diabetes Care Inc TNDM |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-03-28 | 2025-12-31 | 2025-12-31 |
| Revenue | $1.40B | $1.33B | $1.64B | $1.01B |
| Revenue growth (YoY) | +17.5% | -2.0% | +1.5% | +7.9% |
| Gross margin | 67.1% | 59.0% | 50.9% (computed) | 53.8% |
| Operating margin | 13.5% | 11.7% | -30.2% | -18.5% |
| Net margin | 12.7% | 7.3% | -31.6% | -20.2% |
| Net income | $177.69M | $97.31M | -$516.47M | -$204.71M |
| EPS (Diluted) | $4.52 | $2.05 | -$6.74 | -$3.04 |
| Operating cash flow | $238.66M | $293.22M | $50.38M | -$9.72M |
| Free cash flow | $174.93M | $260.44M | -$31.05M | -$29.67M |
| Cash & equivalents | $186.90M | $245.44M | $235.05M | $90.63M |
| Total assets | $1.83B | $2.40B | $3.60B | $881.11M |
| Total liabilities | $398.92M | n/a | $2.56B | $725.94M |
| Shareholders' equity | $1.43B | $796.32M | $1.04B | $155.17M |
| Return on year-end equity | 12.4% | 12.2% | -49.5% | -131.9% |
| Shares outstanding | 39.23M | 45.25M | n/a | 68.29M |
Revenue, most recent five fiscal years
| Fiscal year | Penumbra Inc | Haemonetics Corp | Integra Lifesciences Holdings Corp | Tandem Diabetes Care Inc |
|---|---|---|---|---|
| Latest | $1.40B Ended 2025-12-31 | $1.33B Ended 2026-03-28 | $1.64B Ended 2025-12-31 | $1.01B Ended 2025-12-31 |
| 1 year earlier | $1.19B Ended 2024-12-31 | $1.36B Ended 2025-03-29 | $1.61B Ended 2024-12-31 | $940.20M Ended 2024-12-31 |
| 2 years earlier | $1.06B Ended 2023-12-31 | $1.31B Ended 2024-03-30 | $1.54B Ended 2023-12-31 | $747.72M Ended 2023-12-31 |
| 3 years earlier | $847.13M Ended 2022-12-31 | $1.17B Ended 2023-04-01 | $1.56B Ended 2022-12-31 | $801.22M Ended 2022-12-31 |
| 4 years earlier | $747.59M Ended 2021-12-31 | $993.20M Ended 2022-04-02 | $1.54B Ended 2021-12-31 | $702.80M Ended 2021-12-31 |